J1B-MC-FRCF - ClinicalTrials.gov - NCT04159701
J1B-MC-FRCF - ClinicalTrials.gov - NCT04159701
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Must agree to use appropriate birth control throughout the study
Must have a diagnosis of CSU for at least 6 months
Must have CSU symptoms for at least 8 consecutive weeks despite taking anti-histamines
Must agree to take an anti-histamine every day during the trial
Must be willing to enter information about symptoms in an electronic diary twice a day
Participants must NOT
Must not have a cause, other than CSU, for itching, hives, and/or angioedema (swelling beneath the skin)
Must not have a current or recent active infection requiring antibiotics
Must not have a history of anaphylaxis (severe, life threatening allergic reaction)
Must not have asthma requiring medications other than short acting beta agonists (albuterol, etc.)
Must not have received prior treatment with omalizumab, ligelizumab, or other experimental biologic for CSU
Trial Summary
Conditions the trial is for
Hives
What the trial is testing?
LY3454738, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
60
Trial Dates
November 2019 - September 2021
Trial Phase
2
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Must agree to use appropriate birth control throughout the study
Must have a diagnosis of CSU for at least 6 months
Must have CSU symptoms for at least 8 consecutive weeks despite taking anti-histamines
Must agree to take an anti-histamine every day during the trial
Must be willing to enter information about symptoms in an electronic diary twice a day
Participants must NOT
Must not have a cause, other than CSU, for itching, hives, and/or angioedema (swelling beneath the skin)
Must not have a current or recent active infection requiring antibiotics
Must not have a history of anaphylaxis (severe, life threatening allergic reaction)
Must not have asthma requiring medications other than short acting beta agonists (albuterol, etc.)
Must not have received prior treatment with omalizumab, ligelizumab, or other experimental biologic for CSU
Trial Summary
Conditions the trial is for
Hives
What the trial is testing?
LY3454738, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
60
Trial Dates
November 2019 - September 2021
Trial Phase
2
Trial Locations
Hide locations not currently recruiting